Last viewed: LMDX


Prices are updated after-hours



nasdaq:LMDX LumiraDx Ltd

LMDX | $9.49 | twitter stocktwits trandingview |

(0.0% 1d) (4.1% 1m) (19.5% 1y) (0.0% 2d) (2.4% 3d) (1.9% 7d) (273.62% volume)

Sec Filling | Patents | 2 employees



add to today's watch list email alert is off






Press-releases


LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Published: 2022-01-14 (Crawled : 13:00) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: 0.0% H: 2.78% C: 1.95%

covid-19 covid test
LumiraDx CRP Test Achieves CE Marking
Published: 2022-01-11 (Crawled : 12:30) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: -1.95% H: 4.91% C: 2.92%


LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
Published: 2021-12-23 (Crawled : 12:00) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: 0.77% H: 3.92% C: -2.18%

covid-19 ce mark covid test
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: -0.85% H: 11.78% C: 11.17%

sars-cov-2
Audere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test Kit
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: 2.97% H: 3.74% C: -2.67%

fda covid authorization test merge
FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: 8.54% H: 3.01% C: -7.67%

fda test molecular sars-cov-2
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: -0.23% H: 6.35% C: 2.96%

financial results results conference
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
LMDX | $9.49 | twitter stocktwits trandingview |
| | O: 20.4% H: 3.25% C: -6.7%

covid test india approval
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying